Michael Katz Biography and Net Worth

Major Shareholder of Organogenesis


Mr. Michael Katz is the Major Shareholder of Organogenesis.

What is Michael W. Katz's net worth?

The estimated net worth of Michael W. Katz is at least $212,807.80 as of November 18th, 2022. Mr. Katz owns 73,382 shares of Organogenesis stock worth more than $212,808 as of April 20th. This net worth approximation does not reflect any other assets that Mr. Katz may own. Learn More about Michael W. Katz's net worth.

How do I contact Michael W. Katz?

The corporate mailing address for Mr. Katz and other Organogenesis executives is 85 Dan Road, Canton MA, 02021. Organogenesis can also be reached via phone at (781) 575-0775 and via email at [email protected]. Learn More on Michael W. Katz's contact information.

Has Michael W. Katz been buying or selling shares of Organogenesis?

Michael W. Katz has not been actively trading shares of Organogenesis within the last three months. Learn More on Michael W. Katz's trading history.

Who are Organogenesis' active insiders?

Organogenesis' insider roster includes Albert Erani (Major Shareholder), Dennis Erani (Major Shareholder), Gary Gillheeney (CEO), Michael Katz (Major Shareholder), and Glenn Nussdorf (Director). Learn More on Organogenesis' active insiders.

Are insiders buying or selling shares of Organogenesis?

In the last twelve months, insiders at the sold shares 1 times. They sold a total of 197,921 shares worth more than $864,914.77. The most recent insider tranaction occured on January, 9th when Major Shareholder Albert Erani sold 197,921 shares worth more than $864,914.77. Insiders at Organogenesis own 34.0% of the company. Learn More about insider trades at Organogenesis.

Information on this page was last updated on 1/9/2024.

Michael W. Katz Insider Trading History at Organogenesis

See Full Table

Michael W. Katz Buying and Selling Activity at Organogenesis

This chart shows Michael W. Katz's buying and selling at Organogenesis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Organogenesis Company Overview

Organogenesis logo
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Read More

Today's Range

Now: $2.90
Low: $2.81
High: $2.91

50 Day Range

MA: $3.03
Low: $2.61
High: $3.84

2 Week Range

Now: $2.90
Low: $1.79
High: $4.70

Volume

421,193 shs

Average Volume

913,366 shs

Market Capitalization

$382.68 million

P/E Ratio

72.52

Dividend Yield

N/A

Beta

1.57